Restauration

Last updated on: 02.06.2021

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

In molecular biology, restoration refers to a mutation that restores the original phenotype. Restorations are based on a phenotypic, but not genotypic, restoration of the wild-type phenotype. This distinguishes the process of restoration from that of reversion. In restoration, a gene defect is corrected functionally, i.e. phenotypically, by mutations at other positions of the gene (intragenic) or other genes (intergenic). Reversion, on the other hand, restores the original nucleotide sequence.

Whether restoration or reversion is present can usually be determined by crossing the revertant with the wild type: if organisms or strains with the mutant phenotype occur in the progeny, restoration is present; if the progeny show only the wild-type phenotype, this is a true reversion.

Note(s)This section has been translated automatically.

Reversion mutations play a significant role, for example, in the development of therapy resistance to chemotherapeutic agents of breast and ovarian carcinomas as well as pancreatic and prostate carcinomas. Tumors in these patients tend to lose both copies of the wild-type BRCA gene, making them particularly sensitive to platinum drugs and poly(ADP-ribose) polymerase inhibitors (PARPi), the therapies of choice in these diseases. Pharmacological inhibition of DNA end-joining repair pathways leads to improved drug treatment outcomes by preventing the acquisition of reversion mutations in BRCA genes, for example (Tobalina L et al. 2021).

LiteratureThis section has been translated automatically.

  1. Cisneros L et al. (2017) Ancient genes establish stress-induced mutation as a hallmark of cancer. PLoS One 12:e0176258.
  2. Edgington MPet al (2019) Modeling the mutation and reversal of engineered underdominance gene drives. J Theor Biol 479:14-21.
  3. Tobalina L et al (2021) A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann Oncol 32:103-112.
  4. Tomala K et al (2019) Limits to compensatory mutations: insights from temperature-sensitive alleles. Mol Biol Evol 36:1874-1883.

Last updated on: 02.06.2021